Skip to main content

Table 1 Clinicopathological features in triple-negative breast cancer patients with a DFS > 4 years (%)

From: Disease-free survival landmark analysis: a potential critical endpoint in triple-negative breast cancer

 

ECT arm (n = 125)

TP arm (n = 127)

P value

Ages (median [IQR])

48 (42.0—53.0)

48 (42.5—57.0)

0.49

Menopasusal status

  

0.98

 Premenopausal

75 (60.00)

75 (59.06)

 

 Postmenopausal

50 (40.00)

52 (40.94)

 

Histological type

  

0.20

 Ductal

117 (93.60)

117 (92.13)

 

 Lobular

4 (3.20)

1 (0.79)

 

 Medullary

3 (2.40)

4 (3.15)

 

 Others

1 (0.80)

5 (3.94)

 

Histological grade

  

0.30

 Grade 2

35 (28.00)

25 (19.69)

 

 Grade 3

78 (62.40)

88 (69.29)

 

 Missing or unkown

12 (9.60)

14 (11.02)

 

Ki67

  

0.54

 < 20%

15 (12.00)

13 (10.24)

 

 20% ≤ to < 50%

41 (32.80)

43 (33.86)

 

 ≥ 50%

65 (52.00)

70 (55.12)

 

 Missing or unkown

4 (3.20)

1 (0.79)

 

pT

  

0.35

 pT1

67 (53.60)

67 (52.76)

 

 pT2

56 (44.80)

60 (47.24)

 

 pT3

2 (1.60)

0 (0.00)

 

pN

  

0.42

 pN0

81 (64.80)

93 (73.23)

 

 pN1

35 (28.00)

29 (22.83)

 

 pN2

4 (3.20)

3 (2.36)

 

 pN3

5 (4.00)

2 (1.57)

 

pTNM stage

  

0.53

 stage 1

47 (37.60)

50 (39.37)

 

 stage 2

69 (55.20)

72 (56.69)

 

 stage 3

9 (7.20)

5 (3.94)

 

Intravascular invasion (%)

  

0.27

 Yes

99 (79.20)

110 (86.61)

 

 No

17 (13.60)

10 (7.87)

 

 Missing or unkown

9 (7.20)

7 (5.51)

 

PD-L1 status

  

0.16

 negative

69 (55.20)

57 (44.88)

 

 postive

24 (19.20)

24 (18.90)

 

 Missing or unkown

32 (25.60)

46 (36.22)

 

Surgery

  

0.07

 Radical surgery

94 (75.20)

81 (63.78)

 

 Breast conserving

31 (24.80)

46 (36.22)

 
  1. DFS disease-free survival, ECT, docetaxel or paclitaxel followed by epirubicin plus cyclophosphamide, TP docetaxel or paclitaxel plus carboplatin